AbbVie Stock - analyst consensus and long-term drivers in focus
20.06.2026 - 22:24:33 | ad-hoc-news.de
Edited by ad hoc news Saturday Desk. Verified prior to publication on 06/20/2026, 20:24 UTC. Details in the imprint.
AbbVie (US00287Y1091) heads into the weekend with analysts still focused on valuation, cash flow and earnings visibility. A recent ad hoc news item points to a Buy-leaning consensus and a market value above $300 billion.
All news and analysis on AbbVie stock
Use this hub for background on the stock, valuation context and current coverage.
What the latest coverage says
Ad hoc news cited recent market data showing AbbVie stock around $216 a share and a market cap close to $382 billion. The same piece described the overall analyst view as Buy-leaning and put the average 12-month target near $253.
TrendSpider lists the next earnings date for AbbVie as 07/30/2026. That gives the stock a clear near-term calendar marker, even in the absence of a fresh weekend filing.
What the weekend focus shows
Saturday's focus shifts from a live catalyst to the longer setup. For AbbVie, that means watching consensus, earnings visibility and the durability of its cash generation.
In the article's framing, the stock remains tied to a large, diversified biopharma business rather than a single product cycle. That matters when traders weigh valuation against recurring revenue streams.
What the company sells
AbbVie builds its business around branded medicines in immunology, oncology, neuroscience and aesthetics. Key franchise names include Skyrizi, Rinvoq, Humira and Botox.
Where the stock trades today
The shares of AbbVie (US00287Y1091) trade on the New York Stock Exchange at $216.49 as of 06/18/2026, 16:00 ET.
AbbVie at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- WKN: A1J84E
- Ticker: ABBV
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): $216.49
- Market cap: $382.56 billion (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: S&P 500
- Next earnings date: 07/30/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
